Last updated on July 2019

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 Followed by PNEUMOVAX 23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018/PNEU-WAY)


Brief description of study

This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in pneumococcal vaccine-nave adults infected with HIV and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX23 when administered 8 weeks after receipt of either V114 or Prevnar 13.

Clinical Study Identifier: NCT03480802

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.